Short Interest in Pasithea Therapeutics Corp. (NASDAQ:KTTA) Expands By 641.7%

Pasithea Therapeutics Corp. (NASDAQ:KTTA) was the target of a significant increase in short interest in February. As of February 15th, there was short interest totalling 26,700 shares, an increase of 641.7% from the January 31st total of 3,600 shares. Currently, 2.6% of the company’s stock are sold short. Based on an average daily trading volume, of 1,040,000 shares, the days-to-cover ratio is presently 0.0 days.

Pasithea Therapeutics Trading Down 5.4 %

Shares of NASDAQ:KTTA opened at $1.22 on Friday. The business’s 50-day simple moving average is $2.28 and its 200 day simple moving average is $3.40. Pasithea Therapeutics has a one year low of $1.12 and a one year high of $9.25.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.